Treatment of Stage I and II Hodgkin's Disease with NOVP (Mitoxantrone, Vincristine, Vinblastine, Prednisone) and Radiotherapy

References

• Mauch P M. Controversies in the management of early stage Hodgkin's disease. Blood 1994; 83: 318–329
   PubMed Web of Science ®Google Scholar
• Brusamolino E, Lazzarino M, Orlandi E. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy. Ann Oncol 1994; 5: S101–S106, (suppl 2)
   PubMed Web of Science ®Google Scholar
• Bonadona G. Modern treatment of malignant lymphomas: a multidisciplinary approach? The Kaplan Memorial Lecture. Ann Oncol 1994; 2: 5–16
   Google Scholar
• Rosemberg S A. Modern combined modality management of Hodgkin's disease. Curr Opin Oncol 1994; 6: 470–472
   PubMedGoogle Scholar
• DeLaney T F, Glatstein E. The role of the staging laparotomy in the management of Hodgkin's disease. Principles and Practice of Oncology updates, S DeVita, Hellman, S A Rosenberg. J. B. Lippincott, Philadelphia 1987; 1–14
   Google Scholar
• Rosemberg S, Kaplan H. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962–1984. Int J Radiat Oncol Biol Phys 1985; 11: 5–22
   PubMed Web of Science ®Google Scholar
• Haybittle J, Hayhoe F G, Esasterling M. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet 1985; 1: 967–972
   PubMed Web of Science ®Google Scholar
• Sutcliffe S B, Gospodarowick M K, Bergsage D E. Prognostic groups for management of localised Hodgkin's disease. J Clin Oncol 1985; 3: 393–401
   PubMed Web of Science ®Google Scholar
• Carde P, Burguers J MW, Henry-Amar M. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988; 6: 239–252
   PubMed Web of Science ®Google Scholar
• Mauch P, Tarbell N, Weinstein H. Stage IA and IIA supradiaphramatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988; 6: 239–252
   PubMedGoogle Scholar
• Mauch P, Somers R. Controversies in the use of diagnostic staging laparotomy and splenectomy in the management of Hodgkin's disease. Ann Oncol 1992; 3: S41–S43, (suppl 4)
   PubMed Web of Science ®Google Scholar
• Longo D L, Young R C, Wesley M. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295–1306, 1986
   PubMed Web of Science ®Google Scholar
• Longo D L, Glatstein E, Duffey P L. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-years results of a prospective randomised trial. J Clin Oncol 1991; 9: 906–917
   PubMed Web of Science ®Google Scholar
• Pavlovsky S, Maschio M, Santarelli M T. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 1988; 80: 1466–1473
   PubMed Web of Science ®Google Scholar
• Horning S J, Hoppe R T, Hancock S L. Vinblastine, bleomycin and metotrexate: an effective adjuvant in favourable Hodgkin's disease. J Clin Oncol 1988; 6: 1822–1831
   PubMed Web of Science ®Google Scholar
• Canellos G P, Anderson J R, Propert K J. Chemotherapy of advanced Hodgkin's disease with MOPP ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1484
   PubMed Web of Science ®Google Scholar
• Bates N P, Willians M V, Bessell E M. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with invoved-field radiotherapy in clinical staged IA and IIA Hodgkin's disease: A British National Lymphoma Investigation pilot study. J Clin Oncol 1994; 12: 288–296
   PubMed Web of Science ®Google Scholar
• Gobbi P G, Pieresca C, Frassoldati A. Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early favorably presenting, clinically staged Hodgkin's patients: The Gruppo italiano per lo Studio dei Linfomi experience. J Clin Oncol 1996; 14: 527–533
   PubMed Web of Science ®Google Scholar
• Horning S I, Hoppe R T, Mason J, Brown B W, Hancock S L, Baer D, Rosenberg S A. Stanford-Kaiser permanente G1 study for clinical stage I and IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 1997; 15: 1736–1744
   PubMed Web of Science ®Google Scholar
• Hagemeister F B, Fuller L, McLaughlin P. NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis. Ann Oncol 1992; 3: 87–90, (suppl 4)
   PubMedGoogle Scholar
• Hagemeister F B, Purugganan R, Fuller L. Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone and radiotherapy. Semin Hematol 1994; 31: 36–43, (suppl 3)
   PubMed Web of Science ®Google Scholar
• Lister T A, Crowther D, Sutcliffe S B. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–1636
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nomparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Preti A, Hagemeister F B, McLaughlin P. Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches. Ann Oncol 1994; 5: S97–S100, (suppl 2)
   PubMed Web of Science ®Google Scholar
• Hagemeister F B, McLaughlin P, Rodriguez M A, Cox J D, Ha C S, Romaguera J E, Sarris A, Younes A, Bachier C, Preti A, Cabanillas F. The pretreatment serum beta-2 mocroglobulin (β2M) is the most important feature predicting freedom from progression (FFP) in clinically staged (CS) I-II Hodgkin's disease (HD) treated with NOVP and extended field radiotherapy. Blood 1995; 86: 530a
   Google Scholar
• Kaldor J M, Day E N, Clarke E A. Leukemia following Hodgkin's disease. N Engl J Med; 1990; 322: 7–13
   PubMed Web of Science ®Google Scholar
• Cosset I M, Henry-Amar M, Thomas J. Increased pulmonary toxicity in the ABVD arm of the EORTC H6-U trial. Proc Am Soc Clin Oncol 1989; 8: 253
   Google Scholar
• Viviani S, Santoro A, Ragni G. Comparative results of MOPP vs ABVD. Eur J Cancer Oncol; 1985; 21: 601–605
   PubMedGoogle Scholar
• Liang J C, Bailey N M, Gabriel G J. A new chemotherapy regimen for treatment of Hodgkin's disease associated with minimal genotoxicity. Leuk & Lymphoma; 1993; 9: 503–508
   PubMed Web of Science ®Google Scholar
• Meistrich M L, Wilson G, Mathur K. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol 1997; 15: 3488–3495
   PubMed Web of Science ®Google Scholar
• Gospodarowicz M K, Sutcliffe S B, Clark R M. Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone. Intl J Rad Oncol Biol Phys; 1991; 22: 859–865
   Web of Science ®Google Scholar
• Noordijk E M, Carde P, Mandard A-M. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. Ann Oncol; 1994; 5: 107–112
   PubMedGoogle Scholar